Word: biotech
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Armed with such knowledge, younger researchers think they can improve on Folkman's techniques. They prefer a more targeted approach: selectively attacking the various molecules and biochemical signals involved in building a new blood vessel. For instance, researchers at Ixsys, a biotech company in San Diego, have developed an artificial antibody that dissolves the biochemical glue that holds a tumor's capillaries together. Indeed, one of the patients in their safety study exceeded all expectations when two of the tumors in his abdomen shrank 70%. "I've been on the drug now for over a year," says Barry Riccio...
...fact, the tutorial staff in the biochem department recognized the need for mentoring more than 70 years ago and instituted the senior scientist program. Under this program, Faculty volunteers, as well as post-docs and scientists in the biotech industry, act as tutorial leaders for a group of no more than eight undergraduates for a period of three years. Senior scientists sign study-cards, assist their tutees in finding a lab in which to work and often act as thesis advisors...
...studios sensibly scale down. Troubled Universal's modest non-Hulk slate now includes the biotech scare show Virus, the George Clooney caper Out of Sight and Terry Gilliam's dopester saga Fear and Loathing in Las Vegas, with Johnny Depp--not just an anti-summer summer movie but an anti-Hollywood Hollywood movie...
...this case, say Gorman, the announcement has been terrific therapy for Entremed, the biotech company that has licensed Folkman's research. The surge in Entremed's stock price today was also good news for Dr. Folkman's research institution, Children's Hospital in Boston: According to Entremed's 10k filed with the SEC, Children's Hospital owns options on 83,334 shares at $6 a share and a further 50,000 shares at $6.375 a share. (The stock closed Friday at $12 1/16 and today hit a high of $85, before dropping...
...research into anti-angiogenesis is familiar to the medical community, and has been under way for 30 years. Some rival studies may be further along than Folkman's. "Past experience has shown that often when announcements like this are made, if you dig a little deeper you find a biotech company in need of capital," says Gorman. "They're leaving out how difficult it is to get from this stage to something that will actually help people...